Development asset linked to Kyverna Therapeutics in public FDA and regional records.
biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
Kyverna Therapeutics pipeline
Portfolio lens on 31 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kyverna Therapeutics drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in Kyverna Therapeutics's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
eculizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
human normal immunoglobulin (ivig)
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Kyverna Therapeutics's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
ocrelizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
ofatumumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
Development asset linked to Kyverna Therapeutics in public FDA and regional records.
-
ublituximab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Kyverna Therapeutics's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
zilucoplan
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Kyverna Therapeutics's portfolio. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor